HONG KONG – Iceland biopharmaceutical firm Alvotech ehf has joined hands with Japan's Fuji Pharma Co. Ltd. in a deal to commercialize the former's biosimilar portfolio in Japan. Alvotech will develop and supply a few biosimilars from its product pipeline, while Fuji will work on those products' registration and commercialization in Japan. Fuji injected an investment of undisclosed size into the Iceland firm.